153 related articles for article (PubMed ID: 37944495)
1. Multi-kingdom gut microbiota analyses define bacterial-fungal interplay and microbial markers of pan-cancer immunotherapy across cohorts.
Huang X; Hu M; Sun T; Li J; Zhou Y; Yan Y; Xuan B; Wang J; Xiong H; Ji L; Zhu X; Tong T; Ning L; Ma Y; Zhao Y; Ding J; Guo Z; Zhang Y; Fang JY; Hong J; Chen H
Cell Host Microbe; 2023 Nov; 31(11):1930-1943.e4. PubMed ID: 37944495
[TBL] [Abstract][Full Text] [Related]
2. Multi-kingdom microbiota analyses identify bacterial-fungal interactions and biomarkers of colorectal cancer across cohorts.
Liu NN; Jiao N; Tan JC; Wang Z; Wu D; Wang AJ; Chen J; Tao L; Zhou C; Fang W; Cheong IH; Pan W; Liao W; Kozlakidis Z; Heeschen C; Moore GG; Zhu L; Chen X; Zhang G; Zhu R; Wang H
Nat Microbiol; 2022 Feb; 7(2):238-250. PubMed ID: 35087227
[TBL] [Abstract][Full Text] [Related]
3. Characterizations of multi-kingdom gut microbiota in immune checkpoint inhibitor-treated hepatocellular carcinoma.
Zhu C; Zhang C; Wang S; Xun Z; Zhang D; Lan Z; Zhang L; Chao J; Liang Y; Pu Z; Ning C; Sang X; Yang X; Wang H; Jiang X; Zhao H
J Immunother Cancer; 2024 Jun; 12(6):. PubMed ID: 38844407
[TBL] [Abstract][Full Text] [Related]
4. Gut microbial structural variation associates with immune checkpoint inhibitor response.
Liu R; Zou Y; Wang WQ; Chen JH; Zhang L; Feng J; Yin JY; Mao XY; Li Q; Luo ZY; Zhang W; Wang DM
Nat Commun; 2023 Nov; 14(1):7421. PubMed ID: 37973916
[TBL] [Abstract][Full Text] [Related]
5. Meta-analysis of the gut microbiota in predicting response to cancer immunotherapy in metastatic melanoma.
Limeta A; Ji B; Levin M; Gatto F; Nielsen J
JCI Insight; 2020 Dec; 5(23):. PubMed ID: 33268597
[TBL] [Abstract][Full Text] [Related]
6. Interaction of bacterial genera associated with therapeutic response to immune checkpoint PD-1 blockade in a United States cohort.
Newsome RC; Gharaibeh RZ; Pierce CM; da Silva WV; Paul S; Hogue SR; Yu Q; Antonia S; Conejo-Garcia JR; Robinson LA; Jobin C
Genome Med; 2022 Mar; 14(1):35. PubMed ID: 35346337
[TBL] [Abstract][Full Text] [Related]
7. Multi-cohort analysis of colorectal cancer metagenome identified altered bacteria across populations and universal bacterial markers.
Dai Z; Coker OO; Nakatsu G; Wu WKK; Zhao L; Chen Z; Chan FKL; Kristiansen K; Sung JJY; Wong SH; Yu J
Microbiome; 2018 Apr; 6(1):70. PubMed ID: 29642940
[TBL] [Abstract][Full Text] [Related]
8. Consistent Stool Metagenomic Biomarkers Associated with the Response To Melanoma Immunotherapy.
Olekhnovich EI; Ivanov AB; Babkina AA; Sokolov AA; Ulyantsev VI; Fedorov DE; Ilina EN
mSystems; 2023 Apr; 8(2):e0102322. PubMed ID: 36809182
[TBL] [Abstract][Full Text] [Related]
9. Role of the intestinal microbiome and microbial-derived metabolites in immune checkpoint blockade immunotherapy of cancer.
Hayase E; Jenq RR
Genome Med; 2021 Jun; 13(1):107. PubMed ID: 34162429
[TBL] [Abstract][Full Text] [Related]
10. The impact of microbiota on PD-1/PD-L1 inhibitor therapy outcomes: A focus on solid tumors.
Najafi S; Majidpoor J; Mortezaee K
Life Sci; 2022 Dec; 310():121138. PubMed ID: 36309224
[TBL] [Abstract][Full Text] [Related]
11. Optimizing therapeutic outcomes of immune checkpoint blockade by a microbial tryptophan metabolite.
Renga G; Nunzi E; Pariano M; Puccetti M; Bellet MM; Pieraccini G; D'Onofrio F; Santarelli I; Stincardini C; Aversa F; Riuzzi F; Antognelli C; Gargaro M; Bereshchenko O; Ricci M; Giovagnoli S; Romani L; Costantini C
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35236743
[TBL] [Abstract][Full Text] [Related]
12. [Association between Immunotherapy with Immune Checkpoint Inhibitors(Anti-PD-1 Antibodies)and Intestinal Microbiota].
Ozaki Y; Suzuki Y; Nishiyama K; Suzutani T; Suzuki H
Gan To Kagaku Ryoho; 2021 Sep; 48(9):1096-1099. PubMed ID: 34521783
[TBL] [Abstract][Full Text] [Related]
13. Multi-kingdom gut microbiota analyses define COVID-19 severity and post-acute COVID-19 syndrome.
Liu Q; Su Q; Zhang F; Tun HM; Mak JWY; Lui GC; Ng SSS; Ching JYL; Li A; Lu W; Liu C; Cheung CP; Hui DSC; Chan PKS; Chan FKL; Ng SC
Nat Commun; 2022 Nov; 13(1):6806. PubMed ID: 36357381
[TBL] [Abstract][Full Text] [Related]
14. Alterations of the Gut Microbiome in Hypertension.
Yan Q; Gu Y; Li X; Yang W; Jia L; Chen C; Han X; Huang Y; Zhao L; Li P; Fang Z; Zhou J; Guan X; Ding Y; Wang S; Khan M; Xin Y; Li S; Ma Y
Front Cell Infect Microbiol; 2017; 7():381. PubMed ID: 28884091
[No Abstract] [Full Text] [Related]
15. Modulation of Gut Microbiota to Enhance Effect of Checkpoint Inhibitor Immunotherapy.
Wu J; Wang S; Zheng B; Qiu X; Wang H; Chen L
Front Immunol; 2021; 12():669150. PubMed ID: 34267748
[TBL] [Abstract][Full Text] [Related]
16. Targeting the Gut Microbiome to Mitigate Immunotherapy-Induced Colitis in Cancer.
Chang AE; Golob JL; Schmidt TM; Peltier DC; Lao CD; Tewari M
Trends Cancer; 2021 Jul; 7(7):583-593. PubMed ID: 33741313
[TBL] [Abstract][Full Text] [Related]
17. The intimate relationship between gut microbiota and cancer immunotherapy.
Elkrief A; Derosa L; Zitvogel L; Kroemer G; Routy B
Gut Microbes; 2019; 10(3):424-428. PubMed ID: 30339501
[TBL] [Abstract][Full Text] [Related]
18. Role of the gut microbiome for cancer patients receiving immunotherapy: Dietary and treatment implications.
Lee KA; Shaw HM; Bataille V; Nathan P; Spector TD
Eur J Cancer; 2020 Oct; 138():149-155. PubMed ID: 32889369
[TBL] [Abstract][Full Text] [Related]
19. Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies.
Lu Y; Yuan X; Wang M; He Z; Li H; Wang J; Li Q
J Hematol Oncol; 2022 Apr; 15(1):47. PubMed ID: 35488243
[TBL] [Abstract][Full Text] [Related]
20. Multimodal metagenomic analysis reveals microbial single nucleotide variants as superior biomarkers for early detection of colorectal cancer.
Gao W; Gao X; Zhu L; Gao S; Sun R; Feng Z; Wu D; Liu Z; Zhu R; Jiao N
Gut Microbes; 2023 Dec; 15(2):2245562. PubMed ID: 37635357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
